WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010151770) METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/151770    International Application No.:    PCT/US2010/039999
Publication Date: 29.12.2010 International Filing Date: 25.06.2010
IPC:
A61K 39/395 (2006.01), C07K 16/22 (2006.01)
Applicants: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, NY 10591 (US) (For All Designated States Except US).
NOGUERA-TROISE, Irene [ES/US]; (US) (For US Only).
THURSTON, Gavin [US/US]; (US) (For US Only).
THIBAULT, Alain [CA/US]; (US) (For US Only)
Inventors: NOGUERA-TROISE, Irene; (US).
THURSTON, Gavin; (US).
THIBAULT, Alain; (US)
Agent: YOKOYAMA, Izumi; Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 (US)
Priority Data:
61/220,465 25.06.2009 US
61/301,881 05.02.2010 US
Title (EN) METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT
(FR) MÉTHODE DE TRAITEMENT DU CANCER PAR UN ANTAGONISTE DE LA PROTÉINE DLL4 ET UN AGENT CHIMIOTHÉRAPEUTIQUE
Abstract: front page image
(EN)The invention provides methods for treating various types of cancer/tumor by administering the combination of DII4 antagonists, in particular, DII4 antibodies and fragments thereof that specifically bind human DII4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing DII4 antagonists and chemotherapeutic agents are also provided.
(FR)L'invention a pour objet des méthodes de traitement de divers types de cancer/tumeur par l'administration de la combinaison d'antagonistes de la protéine Dll4, en particulier, des anticorps anti-Dll4 et leurs fragments qui se lient spécifiquement à la protéine Dll4 humaine, et d'agents chimiothérapeutiques. Ces polythérapies présentent des effets synergiques comparativement au traitement par l'un ou l'autre agent seul. Ainsi, les méthodes de l'invention sont particulièrement bénéfiques pour les patients cancéreux qui présentent une faible tolérance aux effets secondaires provoqués par des dosages élevés nécessaires pour le traitement par l'un ou l'autre agent seul, en pouvant réduire les posologies efficaces. L'invention concerne également des compositions pharmaceutiques et des kits contenant des antagonistes de la protéine Dll4 et des agents chimiothérapeutiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)